Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Jul 27

PMID 39062171

Authors

Mahija Cheekati

Irina Murakhovskaya

Affiliations

Soon will be listed here.

Abstract

Although rituximab is not specifically approved for the treatment of warm autoimmune hemolytic anemia (WAIHA), the First International Consensus Group recommends considering its use as part of the initial therapy for patients with severe disease and as a second-line therapy for primary WAIHA. Some patients do not respond to rituximab, and relapses are common. These relapses are associated with elevated B-cell-activating factor (BAFF) levels and the presence of quiescent long-lived plasma cells (LLPCs) in the spleen. A new group of immunomodulatory drugs, B-cell-activating factor inhibitors (BAFF-i), demonstrated efficacy in multiple autoimmune diseases and have the potential to improve WAIHA treatment outcomes by targeting B-cells and LLPCs. This article reviews the role of BAFF in autoimmune disorders and the currently available literature on the use of BAFF-directed therapies in various immunologic disorders, including WAIHA. Collectively, the clinical data thus far shows robust potential for targeting BAFF in WAIHA therapy.

References

Cooper N, Arnold D . The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010; 149(1):3-13. DOI: 10.1111/j.1365-2141.2010.08076.x. View

Genovese M, Silverman G, Emery P, Gupta R, Gill A, Veenhuizen M . Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population: Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O). J Clin Rheumatol. 2015; 21(5):231-8. DOI: 10.1097/RHU.0000000000000276. View

Vital E, Dass S, Buch M, Henshaw K, Pease C, Martin M . B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum. 2011; 63(10):3038-47. DOI: 10.1002/art.30466. View

Murakhovskaya I . Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med. 2020; 9(12). PMC: 7763062. DOI: 10.3390/jcm9124034. View

Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J . A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024; 105(6):1306-1315. DOI: 10.1016/j.kint.2024.03.012. View

Stohl W . Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development?. Curr Rheumatol Rep. 2012; 14(4):303-9. DOI: 10.1007/s11926-012-0254-6. View

Wallace D, Navarra S, Petri M, Gallacher A, Thomas M, Furie R . Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2012; 22(2):144-54. DOI: 10.1177/0961203312469259. View

Stohl W, Hiepe F, Latinis K, Thomas M, Scheinberg M, Clarke A . Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012; 64(7):2328-37. PMC: 3350827. DOI: 10.1002/art.34400. View

Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet A . Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev. 2014; 14(4):304-13. DOI: 10.1016/j.autrev.2014.11.014. View

10.

Seyler T, Park Y, Takemura S, Bram R, Kurtin P, Goronzy J . BLyS and APRIL in rheumatoid arthritis. J Clin Invest. 2005; 115(11):3083-92. PMC: 1257539. DOI: 10.1172/JCI25265. View

11.

Thai L, Le Gallou S, Robbins A, Crickx E, Fadeev T, Zhou Z . BAFF and CD4 T cells are major survival factors for long-lived splenic plasma cells in a B-cell-depletion context. Blood. 2018; 131(14):1545-1555. DOI: 10.1182/blood-2017-06-789578. View

12.

Breslin W, Hilbish K, Martin J, Halstead C, Edwards T . Developmental Toxicity and Fertility Assessment in Rabbits with Tabalumab: A Human IgG4 Monoclonal Antibody. Birth Defects Res B Dev Reprod Toxicol. 2015; 104(3):117-28. DOI: 10.1002/bdrb.21147. View

13.

Stohl W, Merrill J, Looney R, Buyon J, Wallace D, Weisman M . Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015; 17:215. PMC: 4545922. DOI: 10.1186/s13075-015-0741-z. View

14.

Wong D, Roy N, Zhang K, Anukanth A, Asthana A, Shirkey-Son N . A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. 2022; 13(1):217. PMC: 8752722. DOI: 10.1038/s41467-021-27853-w. View

15.

Isenberg D, Petri M, Kalunian K, Tanaka Y, Urowitz M, Hoffman R . Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2015; 75(2):323-31. DOI: 10.1136/annrheumdis-2015-207653. View

16.

Xiao Z, Murakhovskaya I . Development of New Drugs for Autoimmune Hemolytic Anemia. Pharmaceutics. 2022; 14(5). PMC: 9147507. DOI: 10.3390/pharmaceutics14051035. View

17.

Mahevas M, Azzaoui I, Crickx E, Canoui-Poitrine F, Gobert D, Languille L . Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial. Haematologica. 2020; 106(9):2449-2457. PMC: 8409028. DOI: 10.3324/haematol.2020.259481. View

18.

Baker K, Edwards B, Main S, Choi G, Wager R, Halpern W . Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003; 48(11):3253-65. DOI: 10.1002/art.11299. View

19.

Manzi S, Sanchez-Guerrero J, Merrill J, Furie R, Gladman D, Navarra S . Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012; 71(11):1833-8. PMC: 3465857. DOI: 10.1136/annrheumdis-2011-200831. View

20.

Merrill J, van Vollenhoven R, Buyon J, Furie R, Stohl W, Morgan-Cox M . Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind,.... Ann Rheum Dis. 2015; 75(2):332-40. DOI: 10.1136/annrheumdis-2015-207654. View